Drugs / Cilostazol
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PLETAL | — | 2007-01-18 | fda.gov ↗ |
| Approved | US (FDA) | PLETAL | — | 1999-01-15 | fda.gov ↗ |
Trials 104 · started per year
today
US approved 1999
1
2
2
8
1
3
6
4
7
6
6
3
6
1
4
6
6
2
4
5
4
4
3
7
3
1992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07588932 | May 2026 → Dec 2027 expected | stroke disorder | Spaulding Rehabilitation Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT02253004 | Sep 2014 → Aug 2015 | migraine with aura, stroke disorder | Herlev Hospital | Completed | No outcome recorded |
| Phase 118 trials · 1 met primary | ||||||
| Phase 1 | NCT06167265 | Nov → Dec 2023 | intermittent vascular claudication | Genovate Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05466734 | Jul → Aug 2022 | intermittent vascular claudication | Genovate Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03524963 | Aug 2017 → May 2018 | peripheral arterial disease | Bundang CHA Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03471169 | Apr 2017 → Dec 2018 | cerebrovascular disorder | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 1 | NCT06568133 | Mar → Jul 2017 | — | Korea United Pharm. Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02554721 | Aug 2015 → Mar 2018 | — | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02625714 | Jun → Jul 2015 | arterial occlusion | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01870466 | Jun 2012 → Sep 2013 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01383395 | Jun → Sep 2011 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01455558 | Feb → Aug 2009 | — | Severance Hospital | Completed | Mixed |
| Phase 1 | NCT00773630 | Dec 2008 → Mar 2009 | intermittent vascular claudication | Otsuka Frankfurt Research Institute GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00689858 | May 2007 → Jul 2008 | — | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00685802 | Jun → Jul 2004 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00684762 | Mar 2004 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00648388 | Mar → May 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00839930 | Feb 2004 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00881231 | Jan → Feb 2004 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00838630 | Nov 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04789837 | Mar 2021 → Dec 2024 | osteoarthritis | Sadat City University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04761848 | Feb 2021 → Oct 2024 | NAFLD1 | Sadat City University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04753970 | Feb 2021 → Jun 2026 overdue | cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1, cerebrovascular disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03109288 | Aug 2017 → Jan 2027 expected | multiple sclerosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 211 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT06504576 | Jun 2025 → Jan 2027 expected | intracerebral hemorrhage | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06612593 | Oct 2024 → Oct 2025 overdue | Parkinson disease | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06492070 | Aug 2024 → Dec 2026 expected | cervical carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma +1 | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT06138834 | Nov 2023 → Nov 2024 | ischemic stroke, large artery stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05126836 | Sep 2021 → Jun 2022 | diastolic heart failure | University of Minnesota | Completed | Met primary |
| Phase 2 | NCT06268470 | Jun 2018 → Mar 2024 | chronic urticaria | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 2 | NCT02481323 | Mar 2016 → Aug 2017 | cognitive disorder, stroke disorder | University of Edinburgh | Completed | No outcome recorded |
| Phase 2 | NCT02491268 | May 2015 → Aug 2020 | cognitive impairment with or without cerebellar ataxia | National Cerebral and Cardiovascular Center, Japan | Completed | Missed primary |
| Phase 2 | NCT01915069 | Jul 2013 → Aug 2014 | — | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT01444885 | Oct 2011 → Jul 2012 | Prinzmetal angina | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT01142284 | May 2010 → Nov 2012 | peripheral arterial disease | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05671497 | Nov 2022 → Oct 2024 | rheumatoid arthritis | Ain Shams University | Completed | No outcome recorded |
| Phase 317 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT06919835 | Aug 2026 → Jul 2029 expected | stroke disorder | Northern California Institute of Research and Education | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07174414 | Aug 2026 → Jul 2031 expected | myocardial infarction, transient ischemic attack | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07144956 | Dec 2025 → Dec 2029 expected | acquired aneurysmal subarachnoid hemorrhage | Centre Hospitalier St Anne | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07249853 | Nov 2025 → May 2027 expected | acquired aneurysmal subarachnoid hemorrhage | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07040085 | Aug 2025 → Jun 2027 expected | stroke disorder | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06989697 | Jan 2025 → Dec 2026 expected | CGF1, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06530537 | Jul 2024 → Aug 2031 expected | stroke disorder | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07600385 | Mar 2019 → May 2022 | peripheral arterial disease | Korea United Pharm. Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03318276 | Feb 2017 → Oct 2018 | peripheral arterial disease | SK Chemicals Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02770274 | Dec 2016 → Dec 2021 | peripheral arterial disease | Attikon Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT06886620 | Mar 2016 → Feb 2017 | intermittent vascular claudication | Genovate Biotechnology Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT02094469 | Dec 2013 → Jan 2016 | coronary vasospasm | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02087007 | Nov 2013 → Jul 2015 | coronary vasospasm | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02266030 | Feb 2011 → Nov 2016 | coronary artery disorder | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00333164 | May 2006 → Mar 2012 | cerebrovascular disorder | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | No outcome recorded |
| Phase 3 | NCT00202020 | May 2004 → Jan 2006 | cerebral infarction | Otsuka Beijing Research Institute | Completed | Missed primary |
| Phase 3 | NCT00766545 | Apr 1992 → Mar 1997 | cerebral infarction | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 442 trials · 10 met primary · 4 missed | ||||||
| Phase 4 | NCT07180472 | Sep 2025 → Sep 2027 expected | — | First Affiliated Hospital of Chengdu Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06757764 | Jul 2025 → Mar 2028 expected | cerebral artery stenosis, cerebral infarction | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05445895 | Dec 2022 → Oct 2025 | ischemic stroke | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT05906199 | Jul 2021 → Jun 2023 | diabetic peripheral angiopathy | SK Chemicals Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT04148105 | Nov 2019 → May 2023 | acquired aneurysmal subarachnoid hemorrhage | Henry Ford Health System | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06522113 | Jul 2019 → Oct 2022 | transient ischemic attack | Incheon St.Mary's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03581409 | Oct 2018 → Jan 2021 | brain aneurysm | Seoul National University Hospital | Completed | Met primary |
| Phase 4 | NCT02829151 | Feb 2017 → Oct 2021 | limb ischemia | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT02933788 | Oct → Dec 2016 | type 2 diabetes mellitus | Kangbuk Samsung Hospital | Unknown | Missed primary |
| Phase 4 | NCT03248401 | Sep 2016 → Oct 2018 | atherosclerosis, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04407312 | Jan 2016 → Dec 2018 | acute myocardial infarction | Gyeongsang National University Hospital | Unknown | Met primary |
| Phase 4 | NCT01995370 | Dec 2013 → Dec 2018 | cerebral infarction | Japan Cardiovascular Research Foundation | Completed | Met primary |
| Phase 4 | NCT01955200 | Oct 2013 → Dec 2016 | coronary artery disorder | The First Affiliated Hospital with Nanjing Medical University | Completed | Met primary |
| Phase 4 | NCT01932203 | Jul 2013 → Aug 2019 | cerebrovascular disorder | Inha University Hospital | Unknown | Missed primary |
| Phase 4 | NCT01711333 | Oct 2012 → May 2014 | peripheral arterial occlusive disease 1 | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03116269 | Mar 2012 → Oct 2014 | ischemic stroke | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01261832 | Jul 2011 → Feb 2020 | acute myocardial infarction | Korea University Guro Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01346865 | May 2011 → Feb 2015 | coronary artery disorder | CardioVascular Research Foundation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01354808 | Jul 2010 → Jul 2012 | myocardial stunning, platelet aggregation, spontaneous | Gyeongsang National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01267734 | Jun 2010 → Dec 2011 | coronary artery disorder | Seoul National University Hospital | Unknown | Met primary |
| Phase 4 | NCT01409564 | May 2010 → Jun 2012 | Alzheimer disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00938522 | Jul 2009 → Dec 2010 | — | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01013532 | Jun 2009 → Sep 2016 | brain ischemia, intracerebral hemorrhage | Asan Medical Center | Unknown | Mixed |
| Phase 4 | NCT02483169 | Jun 2009 → Sep 2016 | brain ischemia, intracerebral hemorrhage | Asan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01094457 | Mar 2009 → Apr 2012 | acute coronary syndrome | Shenyang Northern Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00823875 | Mar → Dec 2009 | cerebral infarction | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00912756 | Mar 2009 → Jun 2012 | arteriosclerosis obliterans | Kansai Rosai Hospital | Unknown | Met primary |
| Phase 4 | NCT00823849 | Oct 2008 → Aug 2009 | arteriosclerosis obliterans, type 2 diabetes mellitus | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00847860 | Mar 2008 → May 2011 | stroke disorder, vascular dementia | Peking University First Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00589927 | Dec 2007 → Dec 2009 | coronary artery disorder | CardioVascular Research Foundation, Korea | Completed | Met primary |
| Phase 4 | NCT00573950 | Dec 2007 → Dec 2008 | metabolic syndrome X, type 2 diabetes mellitus | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00549978 | Oct 2007 → May 2008 | — | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00446641 | Mar 2007 → Jun 2008 | cerebral infarction | Asan Medical Center | Completed | Missed primary |
| Phase 4 | NCT00431249 | Feb 2007 → Apr 2008 | peripheral arterial disease | Tungs' Taichung Metroharbour Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00404781 | Jun 2006 → Jun 2007 | acute coronary syndrome | Shenyang Northern Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00272454 | Jan 2006 → Sep 2008 | cerebral infarction | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT00130039 | Aug 2005 → Jan 2009 | atherosclerosis, cerebral infarction | Asan Medical Center | Completed | Missed primary |
| Phase 4 | NCT00404716 | Dec 2004 → Feb 2007 | acute coronary syndrome | Shenyang Northern Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01076478 | Mar 2004 → Nov 2009 | polyneuropathy | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00234065 | Dec 2003 → Dec 2008 | cerebral infarction | Otsuka Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT00048776 | Oct 2001 → Jun 2003 | Raynaud disease | Otsuka America Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT00048763 | Oct 2001 → Jun 2003 | Raynaud disease | Otsuka America Pharmaceutical | Completed | No outcome recorded |
| Phase not applicable9 trials · 1 met primary · 1 missed | ||||||
| — | NCT06058130 | Sep 2023 → Oct 2025 | atrial fibrillation, carotid stenosis, intracranial arteriosclerosis, ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT06053021 | Sep 2023 → Oct 2025 | ischemic stroke, thrombocytopenia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT05595993 | Oct 2022 → Dec 2023 | — | Danish Headache Center | Unknown | Met primary |
| — | NCT04069819 | Aug 2019 → Dec 2021 | major depressive disorder | Sadat City University | Completed | No outcome recorded |
| — | NCT02549898 | Aug 2015 → Jun 2018 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
| — | NCT01378650 | Jul 2011 → Jun 2013 | tinnitus | Jong Woo Chung | Completed | No outcome recorded |
| — | NCT01261234 | Dec 2010 → Mar 2019 | carotid stenosis | Kobe City General Hospital | Completed | Missed primary |
| — | NCT01872858 | Nov 2010 → Nov 2012 | cognitive impairment with or without cerebellar ataxia | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT00620646 | Feb → Dec 2008 | — | Samsung Medical Center | Completed | No outcome recorded |
| Comparator or background therapy54 trials | ||||||
| Phase 1 | NCT07286110 Background | Dec 2025 → Nov 2026 expected | Moyamoya disease | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03480321 Comparator | Mar → Apr 2018 | intermittent vascular claudication | Genovate Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02431013 Background | Apr → Aug 2015 | hyperlipidemia, peripheral arterial disease | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT07238985 Comparator | Nov 2025 → Nov 2026 expected | fatty liver disease | Tanta University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05298696 Comparator | Mar → Oct 2022 | breast cancer, peripheral neuropathy | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT05836766 Comparator | Jun 2023 → Jul 2024 | cerebral artery occlusion, ischemic stroke | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03855332 Comparator | Jul 2019 → Dec 2022 | cerebrovascular disorder | University of Oxford | Completed | Missed primary |
| Phase 2 | NCT00783081 Comparator | Nov 2008 → Jul 2010 | intermittent vascular claudication | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00443287 Comparator | Feb 2007 → Oct 2008 | intermittent vascular claudication | Sanofi | Completed | No outcome recorded |
| Phase 2/3 | NCT06117436 Comparator | Oct 2023 → Dec 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT03451591 Comparator | Jan 2018 → May 2022 | stroke disorder | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT06561867 Comparator | Aug 2024 → Nov 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591377 Comparator | Aug 2024 → Sep 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06202755 Comparator | Mar 2024 → Jun 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06196047 Comparator | Dec 2023 → Dec 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06242145 Comparator | Jan 2023 → Jul 2024 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05594680 Comparator | Oct 2022 → Nov 2024 | rheumatoid arthritis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT06242132 Comparator | Jun 2022 → Jul 2024 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT06591351 Comparator | May 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591312 Comparator | May 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591299 Comparator | Apr 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591390 Comparator | Feb 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT01895400 Comparator | Jul 2013 → Dec 2015 | vestibular disorder | Jong Woo Chung | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00891670 Comparator | May → Jun 2009 | coronary stenosis, platelet aggregation, spontaneous | Gyeongsang National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00132743 Comparator | Feb 2007 → Jul 2013 | atherosclerosis, peripheral vascular disease | Joselyn Cerezo, MD | Unknown | No outcome recorded |
| Phase 4 | NCT06402747 Comparator | Apr 2024 → Dec 2026 expected | atherosclerosis, type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03062319 Comparator | Apr 2017 → Jul 2023 | atherosclerosis, atrial fibrillation, ischemic stroke | National Hospital Organization Osaka National Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02983214 Comparator | Nov 2016 → Oct 2019 | ischemic stroke, peripheral arterial disease, type 2 diabetes mellitus | University of Ioannina | Completed | No outcome recorded |
| Phase 4 | NCT02374957 Comparator | Feb 2015 → Jun 2017 | intermittent vascular claudication, peripheral arterial disease | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 4 | NCT02174939 Comparator | Feb 2014 → Oct 2017 | coronary artery disorder | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02098460 Comparator | Oct 2013 → Mar 2016 | hyperlipidemia | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02194686 Comparator | Jan 2013 → Mar 2014 | cardiovascular disorder | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01952756 Comparator | Jan 2012 → Sep 2013 | peripheral arterial disease | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01291641 Comparator | Mar 2011 → Dec 2016 | hyperlipidemia | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01188824 Comparator | Sep 2010 → Jul 2013 | ischemic stroke | China Medical University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01192724 Comparator | Mar 2010 → Dec 2012 | coronary artery disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01252056 Comparator | Mar 2010 → Dec 2012 | diabetic kidney disease | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01031667 Background | Nov 2009 → Jun 2011 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01328470 Comparator | Sep 2009 → Aug 2010 | Prinzmetal angina, chronic kidney disease | Kyunghee University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00915733 Comparator | May → Oct 2009 | myocardial infarction | Gyeongsang National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00886574 Comparator | Apr 2009 → Feb 2011 | type 2 diabetes mellitus | Hanyang University | Unknown | No outcome recorded |
| Phase 4 | NCT00822172 Comparator | Sep 2008 → Nov 2010 | intermittent vascular claudication, peripheral arterial disease | Colorado Prevention Center | Completed | No outcome recorded |
| Phase 4 | NCT01012193 Comparator | Jan 2008 → Jul 2009 | coronary artery disorder | Gyeongsang National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00741286 Comparator | Nov 2006 → Oct 2008 | cerebral infarction | Inje University | Completed | No outcome recorded |
| Phase 4 | NCT00776828 Comparator | Nov 2006 → Jan 2010 | coronary artery disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00272831 Comparator | Dec 2005 → Dec 2007 | type 2 diabetes mellitus | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT07495969 Background | Apr 2026 → Dec 2027 expected | cerebral artery occlusion, ischemic stroke | Feng Gao | Not yet recruiting | No outcome recorded |
| — | NCT04452929 Comparator | Jul 2020 → Feb 2022 | migraine with aura, migraine without aura | Danish Headache Center | Unknown | No outcome recorded |
| — | NCT03422796 Comparator | Nov 2017 → Sep 2018 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT02486276 Comparator | Jun 2015 → Jun 2016 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT01841827 Comparator | Apr → Jun 2013 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT01779401 Comparator | Sep 2012 → Sep 2016 | coronary artery disorder | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| — | NCT01482117 Comparator | Nov 2011 → Jan 2012 | — | Inje University | Completed | No outcome recorded |
| — | NCT01359423 Comparator | Sep 2011 → Aug 2017 | intermittent vascular claudication | Yonsei University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2017-01-27 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Regulatory Otsuka Files a Supplemental Application in Japan: A Plastic Case with Anti-Stroke Medicine for a Smart Medicine Container otsuka.co.jp ↗
Otsuka Pharmaceutical Co., Ltd. today announced the filing of a supplemental application for a plastic case containing the anti-platelet drug Pletaal (cilostazol) OD tablets 100mg to the Japanese Ministry of Health, Labour and Welfare. |
| 2010-09-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results The Antiplatelet Agent Pletaal (Nonproprietary Name: Cilostazol) The Results of CSPS 2, a Large-Scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Posted on the Online Version of The Lancet Neurology® otsuka.co.jp ↗
Tokyo, Japan -- Otsuka Pharmaceutical Co., Ltd. today announced that the results of CSPS 2, a large-scale clinical trial of cilostazol (Product Name: Pletaal) in preventing recurrent strokes, were posted on the online version of The Lancet Neurology, a British major medical journal in neurology, on September 11, 2010.* |
| 2010-03-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results The Results of CSPS II, a Large-scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Presented at American Stroke Association's International Stroke Conference on February 26 otsuka.co.jp ↗
According to the report, patients taking cilostazol were less likely to suffer a stroke or develop bleeding requiring hospitalization compared to patients taking aspirin. |
| 2004-11-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Cilostazol Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Cilostazol Tablets, 50 mg and 100 mg. |
All press releases naming this drug 10 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 162 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cilostazol | “We conducted a prospective, randomized study to evaluate the combination of cilostazol (CTZ) and extract of Ginkgo biloba (EGb) and compare it with aspirin for the prevention...” PMID 40803668 ↗ Aug 2025157“Five hundred patients with non-cardioembolic AIS presenting within 72 h of symptom onset will be randomized to receive either aspirin 100 mg and cilostazol 200 mg plus EGb 761...” PMID 39528058 ↗ Nov 2024 “The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and...” NCT00048763 ↗ “Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with...” NCT01261832 ↗ “In part 1, each subject received a single dose of SR (200 mg × 1 tablet, once daily) and IR (100 mg × 2 tablets, BID) formulations of cilostazol orally 7 days apart in a fasted state.” PMID 22129569 ↗ Nov 2011 “A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease” NCT01711333 ↗ “dabigatran 110mg twice daily or 150mg twice daily+ aspirin 100mg once daily / clopidogrel 75mg once daily / ticagrelor 90mg twice daily / cilostazol 100mg twice daily” NCT06058130 ↗ “Pletaal (Cilostazol) is taken 100mg oral tablets two times a day (bid) during 2 weeks after dosing of Pletaal (Cilostazol) 50mg oral tablets bid during 2 weeks.” NCT01444885 ↗ “Efficacy and Safety of Combined Cilostazol and Rosuvastatin Therapy Versus Rosuvastatin Alone in Patients with Chronic Lower Extremity Peripheral Artery Disease” NCT07600385 ↗ “Y-6 sublingual tablets (each tablet contains 25 mg cilostazol and 6 mg dexborneol) Manufacturer: Nanjing Neurodawn Pharmaceutical Co., Ltd.” NCT05836766 ↗ “We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES).” PMID 21232664 ↗ Jan 2011 |
| Known as | CLS | “Cilostazol (CLS) has shown antidepressant effect in cardiovascular patients, post-stroke depression, and animal models” PMID 34545997 ↗ Sep 2021 |
| Known as | CSZ | “Cilostazol (CSZ), a 2-oxo-quinoline derivative, is a selective inhibitor of phosphodiesterase-3” NCT06612593 ↗ |
| Known as | CTZ | “We conducted a prospective, randomized study to evaluate the combination of cilostazol (CTZ) and extract of Ginkgo biloba (EGb) and compare it with aspirin for the prevention...” PMID 40803668 ↗ Aug 20251“Fifty patients with T2D and carotid atherosclerotic plaques were randomly assigned to either a 200 mg/d cilostazol (CTZ) group or a 100 mg/d aspirin (ASA) group for 6 months.” PMID 32700396 ↗ Sep 2020 |
| Known as | NSC-758936 | ChEMBL registry synonym — accepted as the source's own label CHEMBL799 ↗ |
| Known as | OPC-13013 | ChEMBL registry synonym — accepted as the source's own label CHEMBL799 ↗ |
| Known as | OPC-21 | ChEMBL registry synonym — accepted as the source's own label CHEMBL799 ↗ |
| Known as | Pletaal | “Pletaal (Cilostazol) is taken 100mg oral tablets two times a day (bid) during 2 weeks after dosing of Pletaal (Cilostazol) 50mg oral tablets bid during 2 weeks.” NCT01444885 ↗2“Pletaal(Cilostazol) is taken 100mg oral tablets bid during 2 weeks after dosing of Pletaal(Cilostazol) 50mg oral tablets bid during 2 weeks.” NCT02087007 ↗ “Pletaal® (Cilostazol) 100 mg, bid p.o.” NCT01188824 ↗ |
| Known as | Pletaal (Otsuka pharmaceutical) | “Pletaal (Otsuka pharmaceutical)” NCT00776828 ↗ |
| Known as | Pletaal SR Capsule | “A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease” NCT01711333 ↗ |
| Known as | Pletal | “Pletal® 50 mg Tablet (reference) dosed in first period followed by Cilostazol 50 mg Tablet (test) dosed in second period.” NCT00839930 ↗5“Mylan's cilostazol 100 mg tablets and Otsuka's Pletal® 100 mg tablets” NCT00648388 ↗ “Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)” NCT00881231 ↗ “Cilostazol (Pletal®) 100 mg Tablets” NCT07144956 ↗ |
| Known as | PMR | “The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered...” NCT05466734 ↗2“The study is designed to evaluate the bioequivalency between the test formulations of extended-release tablet of cilostazol (PMR) administered once-daily and the reference...” NCT03480321 ↗ “the test formulation of extended-release tablet of cilostazol (PMR) administered once daily” NCT06167265 ↗ |
| Action | Inhibit | “inhibits the ability of one type of blood cell, platelets, to form blood clots” NCT00048776 ↗1“Phosphodiesterase 3A inhibitor” CHEMBL799 ↗ |
| Modality | Small molecule | “Cilostazol is a quinoline derivative” NCT02983214 ↗ |
| Route | Oral | “Cilostazol 200mg/day Oral” NCT00202020 ↗ |
| Target | PDE3A | “Phosphodiesterase 3A inhibitor” CHEMBL799 ↗ |